Table 2.
Clinical features of patients of SZ (n = 164) according to the specific diagnostic categories.
| N | Alu Median (interquartile range) (ng/ml) | P-value | |
|---|---|---|---|
| Total | 164 | 593.5 (226.8–1337.1) | |
| Gender | 0.4239 | ||
| Male | 85 (51.8%) | 551.9 (229.7–1,167.5) | |
| Female | 79 (48.2%) | 669.4 (216.9–1,544.1) | |
| Psychosis onset age (y) | 0.8873 | ||
| Up to 16 | 47 (28.7%) | 1,059.9 (534.5–1,653.9) | |
| 17 to 24 | 73 (44.5%) | 1,093.9 (424.1–1,584.6) | |
| 25 to 34 | 36 (22.0%) | 1,185.7 (545.4–1,841.3) | |
| 35 or more | 8 (4.9%) | 695.9 (299.4–1,567.8) | |
| Current age (y) | 0.0518 | ||
| 13 to 24 | 83 (50.6%) | 1,061.6 (412.1–1,657.1) | |
| 25 to 34 | 53 (32.3%) | 1,040.4 (497.2–1,579.0) | |
| 35 or more | 28 (17.1%) | 407.6 (238.2–872.0) | |
| Duration of psychosis (in weeks) | 0.1648 | ||
| Up to 12 | 38 (23.2%) | 1,410.3 (585.7–2,014.1) | |
| 13 to 52 | 22 (13.4%) | 476.4 (242.8–1,314.0) | |
| 53 or more | 104 (63.4%) | 1,061.4 (534.2–1,548.2) | |
| Pharmacological treatment (in weeks) | 0.4203 | ||
| Up to 4 | 72 (43.9%) | 852.7 (476.4–1,431.4) | |
| 5 or more | 92 (56.1%) | 1,090.8 (530.9–1,660.4) | |
| Current treatment | 0.3964 | ||
| AP | 119 (72.6%) | 1,061.8 (437.2–1,589.0) | |
| AP+AD | 23 (14.0%) | 744.9 (484.5–2,055.4) | |
| AP+MS | 22 (13.4%) | 1,227.7 (841.2–1,942.4) | |
| Family history | 0.3730 | ||
| Yes | 20 (12.2%) | 1,015.1 (412.1–1,412.3) | |
| No | 144 (87.8%) | 1,087.8 (484.5–1,657.1) |
SZ, schizophrenia; AP, anti-psychotics; AD, antidepressants; MS, mood stabilizers. P < 0.05 was considered statistically significant.